CXCL13 and myeloid sarcoma: These findings suggest that CXCL13 significantly contributes to the impairment of the BSCB by promoting RNF6/Sqstm1‐ubiquitination‐induced autophagy during the progression of EAE, thereby offering a promising diagnostic and therapeutic target for MS.